Korro’s lead program for alpha-1 antitrypsin deficiency wasn’t as potent as anticipated, leading the company to change course ...
The treatment — which could be the first novel antimalarial in decades — showed the ability in testing to combat drug ...
The “plausible mechanism” pathway, outlined by Martin Makary and Vinay Prasad, is designed to help accelerate treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback